Evolutionary dynamics in pre-invasive neoplasia

Current Opinion in Systems Biology

Volumn 2, Issue , 2017, Pages 1-8

  Abbosh, Christopher ^a   Venkatesan, Subramanian ^a,b   Janes, Samuel M ^c   Fitzgerald, Rebecca C ^d   Swanton, Charles ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cancer evolution; Field cancerization; Genomic instability; Intratumor heterogeneity; Pre invasive neoplasia

Indexed keywords

B RAF KINASE; BETA CATENIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; PROTEIN P53; TRANSCRIPTION FACTOR SOX10; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR SOX9; WNT PROTEIN;

BARRETT ESOPHAGUS; BASAL CELL CARCINOMA; CANCER GROWTH; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL FATE; CHROMOSOMAL INSTABILITY; CHROMOSOME ABERRATION; CHROMOTHRIPSIS; CLONAL EVOLUTION; COLON ADENOMA; DNA DAMAGE; DYNAMICS; EPIGENETICS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS DYSPLASIA; EVIDENCE BASED MEDICINE; EVOLUTION; FAMILIAL ADENOMATOUS POLYPOSIS; FIELD CANCERIZATION; GENE AMPLIFICATION; GENE DELETION; GENE DOSAGE; GENE INACTIVATION; GENE REARRANGEMENT; GENETIC PREDISPOSITION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOMIC INSTABILITY; GERMLINE MUTATION; HETEROZYGOSITY LOSS; HIGH-GRADE ESOPHAGEAL DYSPLASIA; HUMAN; INVASIVE CARCINOMA; MALIGNANT TRANSFORMATION; MELANOMA; MUTAGENESIS; MUTATIONAL ANALYSIS; NEOPLASM; NONHUMAN; PHENOTYPE; POINT MUTATION; PRE-INVASIVE NEOPLASIA; PROGENY; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; SOMATIC MUTATION; SQUAMOUS CELL CARCINOMA; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; UPREGULATION; UTERINE CERVIX CARCINOMA IN SITU; WHOLE EXOME SEQUENCING;

EID: 85017343509     PISSN: None     EISSN: 24523100     Source Type: Journal    
DOI: 10.1016/j.coisb.2017.02.009     Document Type: Review

References (75)

1. Chen H., Lin F., Xing K., He X. The reverse evolution from multicellularity to unicellularity during carcinogenesis. Nat Commun 2015, 6.
2. Nowell P. The clonal evolution of tumor cell populations. Science 1976, 194:23-28.
3. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366:883-892.
4. Cooper C.S., Eeles R., Wedge D.C., Van Loo P., Gundem G., Alexandrov L.B., Kremeyer B., Butler A., Lynch A.G., Camacho N., Massie C.E., et al. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet 2015, 47:367-372.
5. Yates L.R., Gerstung M., Knappskog S., Desmedt C., Gundem G., Van Loo P., Aas T., Alexandrov L.B., Larsimont D., Davies H., Li Y., et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med 2015, 21:751-759.
6. Wang J., Cazzato E., Ladewig E., Frattini V., Rosenbloom D.I.S., Zairis S., Abate F., Liu Z., Elliott O., Shin Y.-J., Lee J.-K., et al. Clonal evolution of glioblastoma under therapy. Nat Genet 2016, 48:768-776.
7. Martincorena I., Roshan A., Gerstung M., Ellis P., Van Loo P., McLaren S., Wedge D.C., Fullam A., Alexandrov L.B., Tubio J.M., Stebbings L., et al. Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 2015, 348:880-886.
8. Simons BD Deep sequencing as a probe of normal stem cell fate and preneoplasia in human epidermis. Proc Natl Acad Sci U S A 2016, 113:128-133.
9. Martincorena I., Jones P.H., Campbell P.J. Constrained positive selection on cancer mutations in normal skin. Proc Natl Acad Sci U S A 2016, 113:E1128-E1129.
10. Simons B.D. Reply to martincorena et al.: Evidence for constrained positive selection of cancer mutations in normal skin is lacking. Proc Natl Acad Sci U S A 2016, 113:E1130-E1131.
11. Alexandrov L.B., Nik-Zainal S., Wedge D.C., Aparicio S.A., Behjati S., Biankin A.V., Bignell G.R., Bolli N., Borg A., Borresen-Dale A.L., Boyault S., et al. Signatures of mutational processes in human cancer. Nature 2013, 500:415-421.
12. Petljak M., Alexandrov L.B. Understanding mutagenesis through delineation of mutational signatures in human cancer. Carcinogenesis 2016, 37:531-540.
13. Alexandrov L.B., Jones P.H., Wedge D.C., Sale J.E., Campbell P.J., Nik-Zainal S., Stratton M.R. Clock-like mutational processes in human somatic cells. Nat Genet 2015, 47:1402-1407.
14. Hoang M.L., Kinde I., Tomasetti C., McMahon K.W., Rosenquist T.A., Grollman A.P., Kinzler K.W., Vogelstein B., Papadopoulos N. Genome-wide quantification of rare somatic mutations in normal human tissues using massively parallel sequencing. Proc Natl Acad Sci U S A 2016, 113:9846-9851.
15. Gazdar A.F., Minna J.D. Multifocal lung cancers-clonality vs field cancerization and does it matter?. J Natl Cancer Inst 2009, 101:541-543.
16. Hung J., Kishimoto Y., Sugio K., Virmani A., McIntire D.D., Minna J.D., Gazdar A.F. Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. JAMA 1995, 273:558-563.
17. Tang X., Shigematsu H., Bekele B.N., Roth J.A., Minna J.D., Hong W.K., Gazdar A.F., Wistuba EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res 2005, 65:7568-7572.
18. Jakubek Y., Lang W., Vattathil S., Garcia M., Xu L., Huang L., Yoo S.Y., Shen L., Lu W., Chow C.W., Weber Z., et al. Genomic landscape established by allelic imbalance in the cancerization field of a normal appearing airway. Cancer Res 2016, 76:3676-3683.
19. Forsberg L.A., Rasi C., Pekar G., Davies H., Piotrowski A., Absher D., Razzaghian H.R., Ambicka A., Halaszka K., Przewoznik M., Kruczak A., et al. Signatures of post-zygotic structural genetic aberrations in the cells of histologically normal breast tissue that can predispose to sporadic breast cancer. Genome Res 2015, 25:1521-1535.
20. Deng G., Lu Y., Zlotnikov G., Thor A.D., Smith H.S. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science 1996, 274:2057-2059.
21. Galandiuk S., Rodriguez-Justo M., Jeffery R., Nicholson A.M., Cheng Y., Oukrif D., Elia G., Leedham S.J., McDonald S.A., Wright N.A., Graham T.A. Field cancerization in the intestinal epithelium of patients with Crohn's ileocolitis. Gastroenterology 2012, 142. 855-864 e858.
22. Slaughter D.P., Southwick H.W., Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953, 6:963-968.
23. Shen L., Kondo Y., Rosner G.L., Xiao L., Hernandez N.S., Vilaythong J., Houlihan P.S., Krouse R.S., Prasad A.R., Einspahr J.G., Buckmeier J., et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 2005, 97:1330-1338.
24. Alonso S., Dai Y., Yamashita K., Horiuchi S., Dai T., Matsunaga A., Sanchez-Munoz R., Bilbao-Sieyro C., Diaz-Chico J.C., Chernov A.V., Strongin A.Y., et al. Methylation of MGMT and ADAMTS14 in normal colon mucosa: biomarkers of a field defect for cancerization preferentially targeting elder African-Americans. Oncotarget 2015, 6:3420-3431.
25. Eads C.A., Lord R.V., Kurumboor S.K., Wickramasinghe K., Skinner M.L., Long T.I., Peters J.H., DeMeester T.R., Danenberg K.D., Danenberg P.V., Laird P.W., et al. Fields of aberrant CPG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res 2000, 60:5021-5026.
26. Lee Y.C., Wang H.P., Wang C.P., Ko J.Y., Lee J.M., Chiu H.M., Lin J.T., Yamashita S., Oka D., Watanabe N., Matsuda Y., et al. Revisit of field cancerization in squamous cell carcinoma of upper aerodigestive tract: better risk assessment with epigenetic markers. Cancer Prev Res (Phila) 2011 Dec, 4(12):1982-1992.
27. Hu B., Castillo E., Harewood L., Ostano P., Reymond A., Dummer R., Raffoul W., Hoetzenecker W., Hofbauer G.F., Dotto G.P. Multifocal epithelial tumors and field cancerization from loss of mesenchymal CSL signaling. Cell 2012, 149:1207-1220.
28. Graham T.A., McDonald S.A., Wright N.A. Field cancerization in the GI tract. Future Oncol 2011, 7:981-993.
29. Dotto G.P. Multifocal epithelial tumors and field cancerization: stroma as a primary determinant. J Clin Invest 2014, 124:1446-1453.
30. Middlebrooks C.D., Banday A.R., Matsuda K., Udquim K.I., Onabajo O.O., Paquin A., Figueroa J.D., Zhu B., Koutros S., Kubo M., Shuin T., et al. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors. Nat Genet 2016.
31. Fléjou J.-F. Barrett's oesophagus: from metaplasia to dysplasia and cancer. Gut 2005, 54(Suppl. 1):i6-i12.
32. Jass J.R., Sobin L. Histological Typing of Intestinal Tumours 2012, Springer Science & Business Media.
33. Eide T.J. Risk of colorectal cancer in adenoma-bearing individuals within a defined population. Int J Cancer 1986, 38:173-176.
34. Qiao Y., Hyder A., Bae S.J., Zarin W., O'Neill T.J., Marcon N.E., Stein L., Thein H.-H. Surveillance in patients with Barrett/'s esophagus for early detection of esophageal adenocarcinoma: a systematic review and meta-analysis. Clin Trans Gastroenterol 2015, 6:e131.
35. Conio M., Blanchi S., Lapertosa G., Ferraris R., Sablich R., Marchi S., D'Onofrio V., Lacchin T., Iaquinto G., Missale G., Ravelli P., et al. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. Am J Gastroenterol 2003, 98:1931-1939.
36. Jones S., Chen W.D., Parmigiani G., Diehl F., Beerenwinkel N., Antal T., Traulsen A., Nowak M.A., Siegel C., Velculescu V.E., Kinzler K.W., et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A 2008, 105:4283-4288.
37. Wang K.K., Sampliner R.E. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008, 103:788-797.
38. Barrett M.T., Sanchez C.A., Prevo L.J., Wong D.J., Galipeau P.C., Paulson T.G., Rabinovitch P.S., Reid B.J. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 1999, 22:106-109.
39. Leedham S.J., Preston S.L., McDonald S.A., Elia G., Bhandari P., Poller D., Harrison R., Novelli M.R., Jankowski J.A., Wright N.A. Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus. Gut 2008, 57:1041-1048.
40. Ross-Innes C.S., Becq J., Warren A., Cheetham R.K., Northen H., O'Donovan M., Malhotra S., di Pietro M., Ivakhno S., He M., Weaver J.M.J., et al. Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma. Nat Genet 2015, 47:1038-1046.
41. Martinez P., Timmer M.R., Lau C.T., Calpe S., del Carmen Sancho-Serra M., Straub D., Baker A.-M., Meijer S.L., Ten Kate F.J., Mallant-Hent R.C. Dynamic clonal equilibrium and predetermined cancer risk in Barrett's oesophagus. Nat Commun 2016, 7:12158.
42. Theisen J., Stein H.J., Dittler H.J., Feith M., Moebius C., Kauer W.K.H., Werner M., Siewert J.R. Preoperative chemotherapy unmasks underlying Barrett's mucosa in patients with adenocarcinoma of the distal esophagus. Surg Endosc 2002, 16:671-673.
43. Stachler M.D., Taylor-Weiner A., Peng S., McKenna A., Agoston A.T., Odze R.D., Davison J.M., Nason K.S., Loda M., Leshchiner I., Stewart C., et al. Paired exome analysis of Barrett's esophagus and adenocarcinoma. Nat Genet 2015, 47:1047-1055.
44. Agrawal N., Jiao Y., Bettegowda C., Hutfless S.M., Wang Y., David S., Cheng Y., Twaddell W.S., Latt N.L., Shin E.J., Wang L.-D., et al. Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov 2012 Oct, 2(10):899-905.
45. Merlo L.M.F., Shah N.A., Li X., Blount P.L., Vaughan T.L., Reid B.J., Maley C.C. A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev Res (Phila) 2010, 3:1388-1397.
46. Li X., Galipeau P.C., Paulson T.G., Sanchez C.A., Arnaudo J., Liu K., Sather C.L., Kostadinov R.L., Odze R.D., Kuhner M.K., Maley C.C., et al. Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barrett's esophagus. Cancer Prev Res 2014, 7:114-127.
47. Gu J., Ajani J., Hawk E., Ye Y., Lee J.H., Bhutani M.S., Hofstetter W.L., Swisher S.G., Wang K., Wu X. Genome-wide catalogue of chromosomal aberrations in Barrett's esophagus and esophageal adenocarcinoma: a high-density SNP array analysis. Cancer Prev Res (Phila) 2010, 3:1176-1186.
48. Weaver J.M.J., Ross-Innes C.S., Shannon N., Lynch A.G., Forshew T., Barbera M., Murtaza M., Ong C.-A.J., Lao-Sirieix P., Dunning M.J., Smith L., et al. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat Genet 2014, 46:837-843.
49. Heitmiller R.F., Redmond M., Hamilton S.R. Barrett's esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy. Ann Surg 1996, 224:66-71.
50. Desai T.K., Krishnan K., Samala N., Singh J., Cluley J., Perla S., Howden C.W. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut 2012, 61:970-976.
51. Murugaesu N., Wilson G.A., Birkbak N.J., Watkins T., McGranahan N., Kumar S., Abbassi-Ghadi N., Salm M., Mitter R., Horswell S., Rowan A., et al. Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy. Cancer Discov 2015.
52. Secrier M., Li X., de Silva N., Eldridge M.D., Contino G., Bornschein J., MacRae S., Grehan N., O'Donovan M., Miremadi A., Yang T.-P., et al. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat Genet 2016, 48:1131-1141.
53. Leslie A., Carey F.A., Pratt N.R., Steele R.J.C. The colorectal adenoma-carcinoma sequence. Br J Surg 2002, 89:845-860.
54. Thirlwell C., Will O.C.C., Domingo E., Graham T.A., McDonald S.A.C., Oukrif D., Jeffrey R., Gorman M., Rodriguez-Justo M., Chin-Aleong J., Clark S.K., et al. Clonality assessment and clonal ordering of individual neoplastic crypts shows polyclonality of colorectal adenomas. Gastroenterology 2010, 138. 1441-1454.e1447.
55. Borras E., San Lucas F.A., Chang K., Zhou R., Masand G., Fowler J., Mork M.E., You Y.N., Taggart M.W., McAllister F., Jones D.A., et al. Genomic landscape of colorectal mucosa and adenomas. Cancer Prev Res (Phila) 2016, 9:417-427.
56. Humphries A., Cereser B., Gay L.J., Miller D.S.J., Das B., Gutteridge A., Elia G., Nye E., Jeffery R., Poulsom R., Novelli M.R., et al. Lineage tracing reveals multipotent stem cells maintain human adenomas and the pattern of clonal expansion in tumor evolution. Proc Natl Acad Sci U S A 2013, 110:E2490-E2499.
57. Kang H., Salomon M.P., Sottoriva A., Zhao J., Toy M., Press M.F., Curtis C., Marjoram P., Siegmund K., Shibata D. Many private mutations originate from the first few divisions of a human colorectal adenoma. J Pathol 2015, 237:355-362.
58. Siegmund K.D., Marjoram P., Woo Y.-J., Tavaré S., Shibata D. Inferring clonal expansion and cancer stem cell dynamics from DNA methylation patterns in colorectal cancers. Proc Natl Acad Sci 2009, 106:4828-4833.
59. Sottoriva A., Kang H., Ma Z., Graham T.A., Salomon M.P., Zhao J., Zhao J., Marjoram P., Siegmund K., Press M.F., Shibata D., Curtis C. A big bang model of human colorectal tumor growth. Nat Genet 2015, 47:209-216.
60. Hirsch D., Camps J., Varma S., Kemmerling R., Stapleton M., Ried T., Gaiser T. A new whole genome amplification method for studying clonal evolution patterns in malignant colorectal polyps. Genes Chromosomes Cancer 2012, 51:490-500.
61. Carvalho B., Postma C., Mongera S., Hopmans E., Diskin S., van de Wiel M.A., van Criekinge W., Thas O., Matthäi A., Cuesta M.A., Terhaar sive Droste J.S., et al. Multiple putative oncogenes at the chromosome 20q amplicon contribute to colorectal adenoma to carcinoma progression. Gut 2009, 58:79-89.
62. Burrell R.A., McClelland S.E., Endesfelder D., Groth P., Weller M.-C., Shaikh N., Domingo E., Kanu N., Dewhurst S.M., Gronroos E., Chew S.K., et al. Replication stress links structural and numerical cancer chromosomal instability. Nature 2013, 494:492-496.
63. Frede J., Greulich P., Nagy T., Simons B.D., Jones P.H. A single dividing cell population with imbalanced fate drives oesophageal tumour growth. Nat Cell Biol 2016, 18:967-978.
64. Klein A.M., Brash D.E., Jones P.H., Simons B.D. Stochastic fate of p53-mutant epidermal progenitor cells is tilted toward proliferation by UV B during preneoplasia. Proc Natl Acad Sci U S A 2010, 107:270-275.
65. Patton E.E., Widlund H.R., Kutok J.L., Kopani K.R., Amatruda J.F., Murphey R.D., Berghmans S., Mayhall E.A., Traver D., Fletcher C.D., Aster J.C., et al. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol 2005, 15:249-254.
66. Kaufman C.K., Mosimann C., Fan Z.P., Yang S., Thomas A.J., Ablain J., Tan J.L., Fogley R.D., van Rooijen E., Hagedorn E.J., Ciarlo C., et al. A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation. Science 2016, 351:6272.
67. Larsimont J.C., Youssef K.K., Sanchez-Danes A., Sukumaran V., Defrance M., Delatte B., Liagre M., Baatsen P., Marine J.C., Lippens S., Guerin C., et al. Sox9 controls self-renewal of oncogene targeted cells and links tumor initiation and invasion. Cell Stem Cell 2015, 17:60-73.
68. Youssef K.K., Lapouge G., Bouvree K., Rorive S., Brohee S., Appelstein O., Larsimont J.C., Sukumaran V., Van de Sande B., Pucci D., Dekoninck S., et al. Adult interfollicular tumour-initiating cells are reprogrammed into an embryonic hair follicle progenitor-like fate during basal cell carcinoma initiation. Nat Cell Biol 2012, 14:1282-1294.
69. Boumahdi S., Driessens G., Lapouge G., Rorive S., Nassar D., Le Mercier M., Delatte B., Caauwe A., Lenglez S., Nkusi E., Brohee S., et al. Sox2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature 2014, 511:246-250.
70. Izumchenko E., Chang X., Brait M., Fertig E., Kagohara L.T., Bedi A., Marchionni L., Agrawal N., Ravi R., Jones S., Hoque M.O., et al. Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA. Nat Commun 2015, 6:8258.
71. Trimble C.L., Piantadosi S., Gravitt P., Ronnett B., Pizer E., Elko A., Wilgus B., Yutzy W., Daniel R., Shah K., Peng S., et al. Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res 2005, 11:4717-4723.
72. Bota S., Auliac J.-B., Paris C., Métayer J., Sesboue R., Nouvet G., Thiberville L. Follow-up of bronchial precancerous lesions and carcinoma in situ using fluorescence endoscopy. Am J Respir Crit Care Med 2001, 164:1688-1693.
73. Ross-Innes C.S., Chettouh H., Achilleos A., Galeano-Dalmau N., Debiram-Beecham I., MacRae S., Fessas P., Walker E., Varghese S., Evan T., Lao-Sirieix P.S., et al. Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study. Lancet Gastroenterol Hepatol 2017, 2:23-31.
74. Spira A., Disis M.L., Schiller J.T., Vilar E., Rebbeck T.R., Bejar R., Ideker T., Arts J., Yurgelun M.B., Mesirov J.P., Rao A., et al. Leveraging premalignant biology for immune-based cancer prevention. Proc Natl Acad Sci U S A 2016, 113:10750-10758.
75. Campbell J.D., Mazzilli S.A., Reid M.E., Dhillon S.S., Platero S., Beane J., Spira A.E. The case for a pre-cancer genome atlas (PCGA). Cancer Prev Res (Phila) 2016, 9:119-124.